Skip to content

Comparison Of Loop-Tip Wire Vs Tradictional Technique In The Cannulation Of The Common Bile Duct

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01771419
Enrollment
320
Registered
2013-01-18
Start date
2010-10-31
Completion date
2014-01-31
Last updated
2013-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-ERCP Pancreatitis

Keywords

loop-tip, ERCP, cannulation of CBD

Brief summary

Selective cannulation of common bile duct (CBD) by insertion of a guide-wire seems to be associated with fewer complications and post-ERCP (Endoscopic retrograde cholangiopancreatography) pancreatitis (PEP) rate than the conventional biliary tree access with cannulotome (CT-25 Cook Medical) with contrast injection even if results are conflicting. the aim of our study is to test a new guide-wire (loop-tip wire), with a loop in the tip, for the prevention of PEP and biliary tree access, in PEP high-risk patients.

Interventions

DEVICELoop-tip wire (Cook Medical) for the cannulation of the CBD
DEVICECannulotome CT-25mm Cook Medical

Sponsors

Hospital San Paolo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* high-risk patients for post-ERCP pancreatitis

Exclusion criteria

* age \< 18 years * allargy to the contrast medium * previous biliary or gastric surgery * neoplastic patients * previous biliary or pancreatic sphincterotomy

Design outcomes

Primary

MeasureTime frameDescription
post ERCP pancreatitis rateup to 4 weeksparticipants will be followed for the duration of hospital stay, an expected average of 2 weeks

Secondary

MeasureTime frameDescription
Number of attempts to obtain the cannulation of CBD and number of participants with adverse events as a measure of safety and tolerabilityup to 4 weeksparticipants will be followed for the duration of hospital stay, an expected average of 2 weeks

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026